Cris Luca

Partner, AI and Digital Investments at Sanofi Ventures at Sanofi · Cambridge, United States

Invests in AI

Cris Luca's investor profile lists AI alongside Digital Health & HealthTech, at Series A. The record holds 13 deals, among them Science 37, Empatica and Aetion.

Email Investor

Email Investor

Credits to line up before a Series A round

Cris Luca backs companies at Series A. A few of the larger credit programs on AI Perks for teams at that point:

Portfolio on record

Portfolio companies

  • Science 37
  • Empatica
  • Aetion
  • Trial Library
  • Click Therapeutics, Inc.
  • Common Sensing
  • Medisafe
  • Omada Health
  • Carbon Health
  • QuantHealth
  • Nucleai
  • Medisafe®
  • Novartis

Investment focus

Backs startups in
Artificial Intelligence, Digital Health & HealthTech
Rounds
Series A
Profile
Venture investor
Deals on record
13
Based in
Cambridge, United States

Ready to pitch AI investors?

AI Perks profiles show public professional information only, so there are no contact details here. Continue to find investors, send your pitch and track the replies.

Email Investor

Email Investor

More AI investors on AI Perks

Browse all AI investors

Questions founders ask

Does Cris Luca invest in AI startups?
Yes. Artificial Intelligence is one of the sectors on Cris Luca's investor profile, together with Digital Health & HealthTech. The stages on record are Series A.
Which companies has Cris Luca backed?
The record lists 13 deals, including Science 37, Empatica, Aetion, Trial Library and Click Therapeutics, Inc.. None of them has a perk listed on AI Perks yet.
What credits can a startup claim before pitching Cris Luca?
For a company raising a Series A round, AI Perks lists credits such as Mixpanel (up to $50,000), SendGrid/Twilio (up to $10,000), New Relic (up to $5,000) and Segment (up to $50,000), with each program's terms and how to apply.
Does AI Perks publish investor contact details?
No. AI Perks profiles show public professional information only: name, role, location, stages, sectors and the portfolio on record. To reach investors, continue with the Email Investor button below.Email Investor

Email Investor

Source: public professional information. Is this you? Request removal

Email Investor

Email Investor